At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 95 enrolled
Drug / intervention
Trastuzumab Deruxtecandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm Study of Trastuzumab Deruxtecan (T-DXd) Monotherapy for Patients With HER2-expressing Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Received 2 or More Prior Regimens (DESTINY-Gastric06)
In Brief
A Phase 2 clinical trial evaluating Trastuzumab Deruxtecan for Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. Completed, enrolled 95 participants across 24 sites.
Detailed Summary
This is a Phase II, open-label, single-arm, multicentre, study in China assessing the efficacy and safety of T-DXd in participants with HER2-expressing advanced gastric or GEJ adenocarcinoma who have received at least 2 prior regimens including a fluoropyrimidine agent and a platinum agent
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
CollaboratorsDaiichi Sankyo Co., Ltd.
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartAug 2021
Primary CompletionJun 2023
Study CompletionFeb 2024
TodayJul 2026
First PostedAug 4, 2021
Enrollment StartAug 20, 2021
Primary CompletionJun 16, 2023
Study CompletionFeb 28, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.9 years ago
Interventions
Trastuzumab Deruxtecandrug
Trastuzumab deruxtecan (T-DXd) by intravenous infusion